Stock MPH MEDICURE INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Medicure Inc.

Equities

MPH

CA58469E4085

Market Closed - Toronto S.E.
Other stock markets
 01:17:10 2024-05-28 pm EDT 		5-day change 1st Jan Change
1.03 CAD -5.50% Intraday chart for Medicure Inc. +1.98% -26.43%
May. 28 Medicure Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Apr. 09 Transcript : Medicure Inc., 2023 Earnings Call, Apr 09, 2024

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Medicure : Q1 - March 31, 2024
PU
MEDICURE : REPORTS FINANCIAL RESULTS FOR QUARTER ENDED MARCH 31, 2024 AND ANNUAL GENERAL MEETING DIRECTOR ELECTION RESULTS
PU
Medicure Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
MEDICURE RECEIVES US FDA FAST TRACK DESIGNATION FOR MC-1 FOR PNPO DEFICIENCY
AQ
Transcript : Medicure Inc., 2023 Earnings Call, Apr 09, 2024
Medicure: Q4 Earnings Snapshot
AQ
Medicure Swung to a Loss in 2023 on Lower Sales
MT
Medicure Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
MEDICURE TO PRESENT FINANCIAL RESULTS ON APRIL 9, 2024 CALL at 8:30 AM ET FOR QUARTER AND YEAR ENDED DECEMBER 31, 2023
AQ
MEDICURE ANNOUNCES NEW PARTNERSHIP THROUGH ITS MARLEY DRUG SUBSIDIARY TO PROVIDE BRENZAVVY AS AN AFFORDABLE MEDICATION FOR AMERICANS WITH TYPE 2 DIABETES
AQ
Marley Drug Announces A Partnership with TheracosBio to Distribute A Newly Approved Diabetes Drug, BRENZAVVY
CI
MEDICURE ANNOUNCES FDA PROVIDES COMPLETE APPROVAL TO ENROLL PATIENTS IN ITS PIVOTAL PHASE 3 TRIAL FOR TREATMENT OF RARE PEDIATRIC DISEASE
AQ
Medicure Inc. Announces FDA Provides Complete Approval to Enroll Patients in Its Pivotal Phase 3 Trial for Treatment of Rare Pediatric Disease
CI
Transcript : Medicure Inc., Q3 2023 Earnings Call, Nov 22, 2023
MEDICURE REPORTS FINANCIAL RESULTS FOR QUARTER ENDED SEPTEMBER 30, 2023
AQ
Medicure: Q3 Earnings Snapshot
AQ
Medicure Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
MEDICURE REITERATES ITS COMMITMENT TO PROVIDING EXCEPTIONAL ACCESS TO ITS BRANDED PITAVASTATIN TO PEOPLE LIVING WITH HIV
AQ
MEDICURE REPORTS FINANCIAL RESULTS FOR QUARTER ENDED JUNE 30, 2023
AQ
Transcript : Medicure Inc., Q2 2023 Earnings Call, Jul 31, 2023
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MPH Stock
  4. News Medicure Inc.